Beijing: YishengBio Co., Ltd. (“YishengBio”, the “Company”) announced today the closing of a US$130 million in Series B funding round. The new investment was co-led by Oceanpine and OrbiMed. After completing the Series B funding round, the company’s institutional investors include OrbiMed, Oceanpine, EightRoad, F-Prime Capital, 3W Capital, Hillhouse Capital, Adjuvant Capital, MSA Capital, AIHC, Epiphron Capital, Superstring Capital, Haitong International, etc. This round of funding will strongly support the expansion of the company’s R&D center, accelerate our commercialization strategies including the clinical development of multiple vaccine candidates and the construction of biologics production facilities in China and Singapore.
YishengBio is a global, fully integrated biopharmaceutical company headquartered in Beijing. The company is engaged in discovering, developing, and commercializing innovative biotherapeutics for cancers and infectious diseases using novel PIKA® immunomodulating technology. YishengBio operates in China, the USA, and Singapore with over 500 employees. YishengBio’s YSJA™ rabies vaccine is the first alum-free lyophilized rabies vaccine launched in China. The rabies vaccine has been commercialized in China and has served over 16 million patients for post-exposure protection against rabies.
“We are very pleased to have the support of healthcare investors in the Series B investment,” said David Shao, CEO of YishengBio. “We believe their investments in YishengBio reflect the confidence in our development of novel PIKA® immunomodulating technology, the revenue potential of YSJA™ rabies vaccine, and the market prospectus of our innovative vaccine pipeline. This new round of capital will accelerate the building of our management and R&D teams and will facilitate the growth of our pipeline and construction of production sites both at home and abroad. YishengBio is committed to providing more innovative, safer, and more effective vaccines and biologics for doctors and patients all over the world.”
Xiao Zhang, Managing Director of CEC Capital, said, “We are delighted to support YishengBio’s Series B investment. Vaccines and healthcare sectors have long been the focus of global investment and YishengBio is well-sought after company in innovative vaccines and biologics. We recognized the talented management team and strong capability. We look forward to seeing new milestones by YishengBio after this investment.”